MELBOURNE, Australia, May 02, 2023 (GLOBE NEWSWIRE) — Immuron Limited (IMCIMRNan Australia-based and globally integrated biopharmaceutical company that has developed two commercial oral immunotherapeutics for the treatment of enteric diseases, is pleased to provide a copy of the presentation made by our Chief Executive Officer at the Coffee Microcaps Conference in Melbourne today. Steven Lydeamore.
A copy of the presentation slide is available on the company’s website.
This press release has been authorized by the directors of Immuron Limited.
Travelan® is an orally administered passive immunotherapy that prophylactically reduces the chance of developing travelers’ diarrhea, a digestive tract disease commonly caused by pathogenic bacteria and the toxins they produce. Travelan® is a highly purified tablet formulation of bovine hyperimmune antibodies and other factors that, when taken with meals, bind to diarrhea-causing bacteria and prevent colonization and the pathology associated with travelers’ diarrhea. Travelan in Australia® is a drug listed on the Australian Register for Therapeutic Goods (AUST L 106709) and is said to reduce the risk of travelers’ diarrhea and mild gastrointestinal disorders and is antimicrobial. In Canada Travelan® is a licensed natural health product (NPN 80046016) and is thought to reduce the risk of travelers’ diarrhea. Travelan in the US® is sold as a dietary supplement to protect the digestive tract.
About Traveler’s Diarrhea
Traveler’s diarrhea is a gastrointestinal infection with symptoms that include liquid, watery (and occasionally bloody) stools, abdominal cramps, bloating, and fever. Enteropathogenic bacteria are responsible for most cases, with enterotoxigenic ones